SD

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, November 2, 2023
First grade, Research, HS, AD, PD, Food, Safety, Dana–Farber Cancer Institute, Disease, Abstract, Immunology, Cutaneous T-cell lymphoma, Uveal melanoma, STAT3, International, Physician, GDF15, Webcast, Atopic dermatitis, Therapy, Investment, CTCL, Patient, Administration, Cash, Plasma, Lymphoma, Conference, IRAK4, Development, TPD, ASH, Growth, DL2, Hypotension, DL, Solar cycle 4, Arm, AACR, Thrombocytopenia, Fast Track, PTCL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, Society, SD, Hidradenitis suppurativa, MDM2, Recurrence, Blood, Peripheral T-cell lymphoma, Neutropenia, AML, Merkel-cell carcinoma, Pharmaceutical industry, Vaccine, Fine chemical, Medical device, Angela Merkel, Sanofi, Black Majesty

ET

Key Points: 
  • ET
    WATERTOWN, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today reported financial results for the third quarter ended September 30, 2023, and provided business updates on its pipeline of protein degraders.
  • Collaboration Revenues: Collaboration revenues were $4.7 million for the third quarter of 2023 compared to $9.6 million for the third quarter of 2022.
  • Net Loss: Net loss was $52.9 million for the third quarter of 2023 compared to a net loss of $43.0 million for the third quarter of 2022.
  • Cash and Cash Equivalents: As of September 30, 2023, Kymera had $435 million in cash, cash equivalents, and investments.

Coca-Cola Consolidated Reports Third Quarter and First Nine Months 2023 Results

Retrieved on: 
Wednesday, November 1, 2023
Club, Bang (beverage), III, History, Public expenditure, Energy, News, GAAP, Acquisition, COKE, Growth, SD, Overalls, Calendar, Bank, Video game, Bottled water

CHARLOTTE, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Coca‑Cola Consolidated, Inc. (NASDAQ: COKE) today reported operating results for the third quarter ended September 29, 2023 and the first nine months of fiscal 2023.

Key Points: 
  • CHARLOTTE, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Coca‑Cola Consolidated, Inc. (NASDAQ: COKE) today reported operating results for the third quarter ended September 29, 2023 and the first nine months of fiscal 2023.
  • Standard physical case volume declined 1.4% in the third quarter of 2023 and decreased 2.8% in the first nine months of 2023.
  • Income tax expense for the third quarter of 2023 was $28.9 million, compared to $40.3 million in the third quarter of 2022.
  • The discussion of the operating results for the third quarter ended September 29, 2023 and the first nine months of fiscal 2023 includes selected non-GAAP financial information, such as “adjusted” results.

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Retrieved on: 
Wednesday, November 1, 2023
Female, MTD, BMI, Therapy, ASTS, Life, LVEF, Doxorubicin, Kidney, Quality of life, Male, SD, Life expectancy, Index, Hypertension, Risk, Annual general meeting, RECIST, Cancer, Patient, Toxicity, Diagnosis, Heart failure, Toxic leukoencephalopathy, Pharmaceutical industry

The Phase 1b clinical trial has enrolled 14 ASTS patients (9 female and 5 male) to-date ranging in age from 26 to 81 years (median = 52.5 years) across five dose cohorts.

Key Points: 
  • The Phase 1b clinical trial has enrolled 14 ASTS patients (9 female and 5 male) to-date ranging in age from 26 to 81 years (median = 52.5 years) across five dose cohorts.
  • The trial is currently ongoing and is in the fifth dose level cohort (650 mg/m2).
  • So far, 9 out of the 14 patients have had stable disease (SD, as defined by RECIST 1.1 criteria) after camsirubicin treatment.
  • Camsirubicin was designed to retain the anti-cancer activity while avoiding the irreversible heart damage that is seen with doxorubicin.

Innovative Cellular Therapeutics (ICT) Presented Updated Data of the China-IRB Study of GCC19CART in Metastatic Colorectal Cancer at European Society for Medical Oncology (ESMO) Congress 2023

Retrieved on: 
Tuesday, October 31, 2023
Survival, CAR, IRB, ESMO, DCR, Diarrhea, Neurotoxicity, Congress, SD, Cytokine release syndrome, Oncology, ORR, RECIST, European Society for Medical Oncology, CRS, ICT, Patient, OS, Pharmaceutical industry

ICT presented updated data from its China-IRB study of GCC19CART, its lead product candidate from the Company’s CoupledCAR® technology, being developed to treat patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC) in a poster presentation.

Key Points: 
  • ICT presented updated data from its China-IRB study of GCC19CART, its lead product candidate from the Company’s CoupledCAR® technology, being developed to treat patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC) in a poster presentation.
  • Presentation details were as follows:
    This presentation highlights updated survival data from the 21 subjects who were enrolled in two dose escalation groups in IRB-approved studies in China.
  • The median OS is approximately 24 months in dose level 2 with 4 of the 8 patients still alive.
  • The Company’s Phase 1 study of GCC19CART is enrolling patients with R/R mCRC at multiple sites in the U.S.

ProfoundBio Presents Promising Data on ADC Programs, Including Early Clinical Results of Rinatabart Sesutecan in Ovarian and Endometrial Cancers, at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CR, Rat, Neoplasm, Patient, Pneumonitis, Ovarian cancer, PDT, Trae tha Truth, MPH, Therapy, Endometrial cancer, Pharmacokinetics, Safety, Conjugation, PTK7, MMAE, SITC, Immunotherapy, SD, Bone marrow, ADC, Spacecraft, Breast cancer, Mesothelioma, Lung cancer, Society, Cancer, Cytopenia, Therapeutic index, Fatigue, Fine chemical, Medical imaging, Vaccine, Pharmaceutical industry, Communications satellite, Part

ProfoundBio , a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023).

Key Points: 
  • ProfoundBio , a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023).
  • “We are thrilled to present proof-of-concept data from our novel sesutecan ADC platform with the initial clinical results for Rina-S,” said ProfoundBio Chief Medical Officer Naomi Hunder, M.D.
  • Enrolled patients had the following tumor types: ovarian cancer (n=17), endometrial cancer (n=9), breast cancer (n=3), non-small cell lung cancer (n=5), and mesothelioma (n=2).
  • Superior tumor growth inhibition and tolerability relative to the precedent PTK7-directed ADC cofetuzumab pelidotin were observed in head-to-head preclinical studies.

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Society for Immunotherapy of Cancer, Neoplasm, Patient, FRCP, MDSC, PRS, NSCLC, Poster, PD, Aes, UC, Publication, Vomiting, DCR, Diarrhea, Pembrolizumab, Metastasis, Associate professor, Safety, Conference, Doctor of Philosophy, MBBS, Data, Nausea, CD8, Rash, Cancer immunotherapy, Immunotherapy, Rock, SD, DRAGON, SITC, San Diego Convention Center, Biopsy, Annual general meeting, ORR, University, RECIST, Biomarker, Melanoma, Lung cancer, Society, Therapy, AE, Carcinoma, Spectrochimica Acta Part B, Dermatitis, PR, Toxic epidermal necrolysis, Pharmaceutical industry, Medical imaging, Nightclub, Part

The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.

Key Points: 
  • The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.
  • Data presented continues to support proof of concept for SRK-181 in 28 heavily pretreated patients with ccRCC resistant to anti-PD-1.
  • In the biomarker analysis for ccRCC, levels of circulating granulocytic myeloid-derived suppressor cells (gMDSC) correlated with clinical activity in ccRCC patients treated with SRK-181 in combination with pembrolizumab.
  • “The DRAGON trial has successfully delivered on its objective of demonstrating proof of concept for SRK-181 by showing promising anti-tumor activity.

Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases

Retrieved on: 
Monday, November 6, 2023
Șaeș, ECHO, Acute myeloid leukemia, Physical examination, Aes, Food, Progression-free survival, ECOG, Wireless ambulatory ECG, Treatment, MD, Eastern Cooperative Oncology Group, PFS, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, HIV disease progression rates, SD, Washington University School of Medicine, Clinical trial, Cardiotoxicity, STS, RECIST, ANN, Safety, Vital signs, Patient, Toxicity, Pharmaceutical industry

HOUSTON, Nov. 6, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced the presentation of preliminary efficacy findings from the Phase 2 portion of the Company's ongoing U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).

Key Points: 
  • Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).
  • We look forward to further data readouts from this trial and understanding the full potential of Annamycin for the treatment of STS lung mets."
  • The other subject maintained SD through 8 cycles prior to progressing ~6.9 months after initiating treatment with Annamycin.
  • Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107) visit clinicaltrials.gov and reference identified NCT04887298.

Versa Networks Achieves IPv6 Certification, Ensuring Readiness for Next-Generation Connectivity, Interoperability and Security

Retrieved on: 
Wednesday, November 1, 2023
Technology, Mobile, Wireless, Security, Satellite, Telecommunications, Software, Networks, Hardware, VoIP, Cloud, Engineering, SASE, Government, National Institute of Standards and Technology, Unified, VOS, CSG, Organization, Conformity, SD-WAN, CSX, IPv6, SD, Internet Engineering Task Force, Network, IETF, Medical device, Risk management, Versa

Versa Networks, the global leader in AI/ML-powered Unified Secure Access Service Edge (SASE) and Software Defined WAN (SD-WAN), today announced that it has completed independent testing and was awarded an IPv6 Ready “Gold” Logo certification.

Key Points: 
  • Versa Networks, the global leader in AI/ML-powered Unified Secure Access Service Edge (SASE) and Software Defined WAN (SD-WAN), today announced that it has completed independent testing and was awarded an IPv6 Ready “Gold” Logo certification.
  • The Versa Operating System (VOS) was certified against the National Institute of Standards and Technology’s (NIST’s) USGv6r1 Profile, covering Versa CSG and CSX appliances for SD-WAN and SD-LAN, as well as Versa Cloud Gateways.
  • The IPv6 Ready Logo Program is a conformance and interoperability testing program intended to increase user confidence by demonstrating that IPv6 is available and ready to be used.
  • “The U.S. government’s move toward IPv6-only network environments dramatically increases the need to assure the quality, completeness and interoperability of the IPv6 capabilities in IT products and services,” said Shiva Shenoy, Vice President of Engineering at Versa Networks.

Psync Labs Unveils Industry-first GPT-enabled Smart Home Camera

Retrieved on: 
Wednesday, November 1, 2023
GB, Intelligence, Social media, Jinn, Rotation, Amazon Alexa, GPT, SD, Eye, Privacy, Movement, Hearing, Marketing, Television, Camera, AI: The Somnium Files

SUNNYVALE, Calif., Nov. 1, 2023 /PRNewswire/ -- Psync Labs, Inc., today announces the debut of its pioneering product, Psync Camera Genie S, a first-to-its kind smart home camera that leverages innovative generative AI technology. Compatible with Google Assistant and Amazon Alexa, Psync Camera Genie S is now available for purchase at the official website. 

Key Points: 
  • SUNNYVALE, Calif., Nov. 1, 2023 /PRNewswire/ -- Psync Labs, Inc., today announces the debut of its pioneering product, Psync Camera Genie S, a first-to-its kind smart home camera that leverages innovative generative AI technology.
  • Compatible with Google Assistant and Amazon Alexa, Psync Camera Genie S is now available for purchase at the official website .
  • Psync Labs today announces its pioneering product, Genie S, the firstever generative AI-enabled smart home camera.
  • Unlike conventional smart cameras, the Psync Camera Genie S goes beyond just seeing and hearing.

Colt completes $1.8bn acquisition of Lumen EMEA

Retrieved on: 
Thursday, November 2, 2023
Colt Technology Services, Optimism, SASE, Lumen, Pops, Acquisition, SD, Customer, Lumen Technologies, Partnership, Culture, Tourism, Mobile phone, Colt

LONDON, Nov 2, 2023 - (ACN Newswire) - LONDON, Nov 2, 2023 - (ACN Newswire) - Colt Technology Services (Colt), the digital infrastructure company, today announced it has completed the acquisition of Lumen EMEA for $1.8bn.

Key Points: 
  • LONDON, Nov 2, 2023 - (ACN Newswire) - LONDON, Nov 2, 2023 - (ACN Newswire) - Colt Technology Services (Colt), the digital infrastructure company, today announced it has completed the acquisition of Lumen EMEA for $1.8bn.
  • The closure of the transaction is the final stage in Colt's exclusive agreement with Lumen Technologies, Inc. to purchase Lumen's Europe, Middle East and Africa (EMEA) business.
  • It elevates Colt to one of the world's largest business-to-business-only telecoms companies and an influential global player.
  • As a pioneer for sustainable networks, the acquisition makes Colt one of the most powerful voices in the industry.